About Bioatla (BCAB)
BioAtla, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
- USD0.90
- USD1.00
- USD0.90
- USD2.53
- 29.90%
- 11M
- 750.89k
- 1.09M
- 51M
- 0.24
- -55.10%
Stock News
5 hours ago
Norwood Financial (NWFL): Solid Mid-Year Performance Backed by Attractive Dividend Yield
Yahoo
6 hours ago
Stocks That Stand To Be 'Hurt' By AI Eating The World
SeekingAlpha
yesterday
Where Penn State football coach James Franklin’s $49 million buyout ranks among the biggest of all time
MarketWatch
yesterday
Musk calls for federal troops in San Francisco even as Benioff softens stance
CNBC
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
